Pharco to develop Presidio's NS5A inhibitor PPI-668 for HCV in Kenya
Pharco Pharmaceuticals has entered into an exclusive license agreement to develop and commercialize Presidio’s clinical stage hepatitis C virus (HCV) NS5A inhibitor PPI-668 in Kenya.
With the exclusive license, Pharco will now be able to expand its licensed territory to one or more additional countries in the Middle East and East Africa region.
Pharco Pharmaceuticals vice chairman and chief executive officer Dr Sherine.... Read more »
Posted on : Thursday , 4th December 2014